These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 581104)

  • 1. In vivo resistance and in vitro cellular reactivity against lymphosarcoma cells in immunized mice.
    Colnaghi MI; Ménard S; Pierotti MA
    Tumori; 1978; 64(4):371-82. PubMed ID: 581104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of immunity induced by neuraminidase-treated lymphosarcoma cells in C3H (MTV+) and C3H (MTV-) mice.
    Bekesi JG; Roboz JP; Holland JF
    Isr J Med Sci; 1976; 12(4-5):288-303. PubMed ID: 181351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alloreactivity and tumor antigens: generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells.
    Sensi ML; Parenza M; Parmiani G
    J Natl Cancer Inst; 1983 Feb; 70(2):291-7. PubMed ID: 6571938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effector phenotypes and mechanisms of antitumor immune reactivity of tumor-immunized and tumor-bearing mice in two syngeneic tumors.
    Fuyama S; Komatsu H; Arai S
    Cell Immunol; 1991 Oct; 137(1):200-15. PubMed ID: 1679379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural antibodies directed against murine lymphosarcoma cells.
    Pierotti MA; Colnaghi MI
    J Natl Cancer Inst; 1975 Oct; 55(4):945-9. PubMed ID: 1242399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histocompatibility antigens acting as helper determinants for tumor-associated antigens of murine lymphosarcoma.
    Colnaghi MI
    Eur J Immunol; 1975 Apr; 5(4):241-5. PubMed ID: 1086228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli.
    Fenton RG; Keller CJ; Hanna N; Taub DD
    J Natl Cancer Inst; 1995 Dec; 87(24):1853-61. PubMed ID: 7494229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.
    Campbell MJ; Esserman L; Byars NE; Allison AC; Levy R
    J Immunol; 1990 Aug; 145(3):1029-36. PubMed ID: 2373859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alien H-2 allospecificities in murine chemically-induced tumors.
    Merino F
    Immunol Commun; 1979; 8(5-6):555-62. PubMed ID: 94037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
    Lynch DH; Daynes RA; Hodes RJ
    J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effectiveness of neuraminidase-treated tumor cells as an immunogen in man and experimental animals with leukemia.
    Bekesi JG; Roboz JP; Holland JF
    Ann N Y Acad Sci; 1976; 277(00):313-31. PubMed ID: 1069551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to syngeneic lymphoma cells as a result of immunization with chemically modified allogeneic lymphoma cells in mice.
    Gillette RW; Berringer DC; Wunderlich DA
    J Natl Cancer Inst; 1978 Jun; 60(6):1427-32. PubMed ID: 650705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Syngeneic and allogeneic mouse lymphoma antisera: specificity, reaction with fetal antigen and protective capacity.
    Prager MD; Granatek CH; Ludden CM
    Isr J Med Sci; 1976; 12(4-5):325-33. PubMed ID: 939692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune reactivity in SL2 lymphoma-bearing mice compared with SL2-immunized mice.
    De Weger RA; Wilbrink B; Moberts RM; Mans D; Oskam R; Den Otter W
    Cancer Immunol Immunother; 1987; 24(1):25-36. PubMed ID: 3493070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Host reactivity against clonable tumor cells and the total tumor cell population, studied in a syngeneic murine lymphoma system.
    Gjedde SB
    Acta Pathol Microbiol Immunol Scand C; 1983 Apr; 91(2):101-8. PubMed ID: 6349250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells. An antibody-based mechanism for tumor immunity.
    Bright RK; Shearer MH; Kennedy RC
    J Immunol; 1994 Sep; 153(5):2064-71. PubMed ID: 8051411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-reactions between tumor cells and allogeneic normal tissues. Inhibition of a syngeneic lymphoma outgrowth in H-2 and non-H-2 alloimmune BALB/c mice.
    Parmiani G; Sensi ML; Carbone G; Colombo M; Pierotti M; Ballinari D; Hilgers J; Hilkens J
    Int J Cancer; 1982 Mar; 29(3):323-32. PubMed ID: 7068280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effector cell stimulation-inhibition of in vitro lymphoma cell DNA synthesis and correlation with in vivo antitumor response.
    Gordon WC; Prager MD
    Cancer Res; 1977 Feb; 37(2):507-13. PubMed ID: 832275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preferential generation of killer or helper T-lymphocyte activity directed to the tumour-associated transplantation antigens.
    Fujiwara H; Hamaoka T; Teshima K; Aoki H; Kitagawa M
    Immunology; 1976 Aug; 31(2):239-48. PubMed ID: 1085283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.